Joshua Lehrer-Graiwer
CIK 1789673 · PRESIDENT AND CEO · last filed 2026-05-01
Joshua Lehrer-Graiwer is a PRESIDENT AND CEO who has filed 16 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for FULC, was dated May 1, 2026. Across all open-market trades the lifetime net is −$3.3M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
16
-$3.27M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FULC | Director | — | $3.45 | — | $0 | 1 | 2026-05-01 |
| LENZ Therapeutics, Inc. (GRPH) Delisted | PRESIDENT AND CEO | 1,161,670 | $22.26 | $25.86M | $0 | 3 | 2023-02-23 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Chief Medical Officer | 3,533 | $68.49 | $242.0K | -$3.27M | 12 | 2020-03-09 |
Recent Filings
16 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-01 | FULC | Grant (A) | — | $0 | EDGAR |
| 2023-02-23 | LENZ Therapeutics, Inc. (GRPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-18 | LENZ Therapeutics, Inc. (GRPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-07-01 | LENZ Therapeutics, Inc. (GRPH) Delisted | Mixed | +382,139 | $112.2K | EDGAR |
| 2020-03-09 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | −1,138 | -$111.8K | EDGAR |
| 2020-03-04 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +1,138 | -$39.1K | EDGAR |
| 2020-02-20 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | — | -$56.2K | EDGAR |
| 2020-02-10 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | −3,937 | -$321.0K | EDGAR |
| 2020-02-04 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +4,516 | -$160.3K | EDGAR |
| 2020-01-29 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | — | -$33.8K | EDGAR |